# Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate

> **NCT00156299** · PHASE1 · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 15 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** choline magnesium trisalicylate
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00156299
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Replaced by another study
- **Last updated:** 2013-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00156299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00156299, "Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00156299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*